Delix Therapeutics is applying modern tools of pharmaceutical development to some of nature's most ancient therapies, psychedelics. Through its discovery platform, Delix has identified a new class of non-hallucinogenic versions of psychedelic compounds with favorable safety and therapeutic profiles. Delix is rapidly advancing these psychoplastogen compounds through preclinical and clinical development, with the goal of one day alleviating mental suffering through its FDA-approved, take-home medicines.

Biotechnology

Delix Therapeutics

Delix Therapeutics' headquarters in Boston, MA, United States

Mark Rus

Eliseo Salinas

Matt Gorman

Tricia Mccall

Retsina Meyer

David Olson

Vasudev Bailey

Nick Haft

John Krystal

Florence Wagner

Craig Lindsley

Conor Liston

Jacob Hooker

Stephen Stahl

Michael Cola

Description

People (4)

Milan Chytil

Tricia Mccall

Tyler Wright

Mike Bower

Jobs